Survival Outcomes and Treatment Timing in Glioblastoma Patients

Glioblastoma remains the most aggressive primary brain tumour in adults, with median overall survival rarely exceeding 15–18 months despite multimodal treatment. Outcomes hinge on the extent of surgical resection, molecular markers such as MGMT promoter methylation, and the timing of adjuvant therapies. Early postoperative regrowth—often termed rapid early progression—can emerge before radiotherapy, compromising prognosis. Volumetric and texture analyses of pre-radiation MRI have illuminated growth dynamics that correlate with survival, revealing exponential tumour expansion in many patients. Delays between surgery and the commencement of chemoradiation are common, arising from clinical, logistical or diagnostic factors, and their impact on progression-free and overall survival has been the subject of intense scrutiny. A nuanced understanding of optimal intervals between resection and adjuvant treatment, alongside biomarkers of tumour aggressiveness, is essential to refine guidelines and improve patient stratification in both routine care and clinical trials.

Research from Nature Portfolio

Recent studies have evaluated real-world data to define optimal intervals from surgery to radiotherapy and chemoradiotherapy. One large registry analysis found that an interval of four to eight weeks between resection and radiotherapy conferred the best survival outcomes, while shorter delays in subtotal resections or longer delays after gross total resection were associated with worsened prognosis. In another multi-institutional cohort, the onset of the COVID-19 pandemic did not significantly alter progression-free or overall survival for high-grade glioma patients, though diagnostic and treatment intervals were modestly prolonged. These findings reinforce that adherence to guideline-based timing, without undue haste or delay, supports optimal outcomes and can be maintained even during systemic disruptions.

Survival Outcomes and Treatment Timing in Glioblastoma Patients publication trend

The graph below shows the total number of articles in survival outcomes and treatment timing in glioblastoma patients across all publications each year (not limited to Nature Index journals).

Technical terms

Overall survival (OS): Time from diagnosis or treatment initiation until death from any cause.

Progression-free survival (PFS): Interval during which the tumour does not exhibit clinical or radiological progression.

Rapid early progression (REP): Evidence of tumour regrowth on MRI prior to the start of radiotherapy.

Radiomics: Extraction of high-dimensional quantitative features from medical images to inform diagnosis or prognosis.

Gross total resection (GTR): Surgical removal of all visible tumour as assessed by postoperative imaging.

MGMT promoter methylation: Epigenetic modification of the MGMT gene associated with enhanced sensitivity to alkylating chemotherapy.

References

1. Prediction of Rapid Early Progression and Survival Risk with Pre-Radiation MRI in WHO Grade 4 Glioma Patients. Cancers (2023).
2. Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations. Scientific Reports (2023).
3. Preoperative growth dynamics of untreated glioblastoma: Description of an exponential growth type, correlating factors, and association with postoperative survival. Neuro-Oncology Advances (2024).
4. Optimal Timing of Radiotherapy Following Gross Total or Subtotal Resection of Glioblastoma: A Real-World Assessment using the National Cancer Database. Scientific Reports (2020).
5. Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients. Scientific Reports (2020).